New drug cocktail aims to shrink breast tumors before surgery
NCT ID NCT07383818
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 2 trial is testing whether combining trastuzumab rezetecan (a targeted drug) with toripalimab (an immunotherapy) before surgery can eliminate more tumor tissue in women with HR-positive, HER2-low breast cancer. About 111 participants will receive the drug combo for 24 weeks, then undergo surgery. The main goal is to see how many achieve a pathologic complete response (no cancer cells left in the breast).
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
trastuzumab rezetecan and toripalimab
What this could lead to
If successful, this combination could become a new pre-surgery treatment option for HR+/HER2-low breast cancer, potentially improving tumor clearance and long-term outcomes.
What could go wrong
This is an early Phase 2 trial with only 111 participants, so results may not apply to all patients. The combination may cause side effects, and it is not yet known if it improves survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HR POSITIVE/HER2 LOW BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Harbin Medical University Cancer Hospital
RECRUITINGHarbin, China
Contact
-
The First Affiliated Hospital of Anhui Medical University
RECRUITINGHefei, China
Contact
-
The Second Affiliated Hospital of Xi'an Jiaotong University
RECRUITINGXi'an, China
Contact
-
The Second Affiliated Hospital of Xi'an Jiaotong University
RECRUITINGZhengzhou, China
Contact
-
Zhongshan Hospital, Fudan University
RECRUITINGShanghai, China
Contact